In the BioHarmony Drug Report Database

"Preview" Icon

Ipratropium

Atrovent, Atrovent Hfa (ipratropium) is a small molecule pharmaceutical. Ipratropium was first approved as Atrovent on 1986-12-29. It is used to treat allergic rhinitis perennial, bronchial spasm, bronchitis, pulmonary emphysema, and vasomotor rhinitis in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M5, muscarinic acetylcholine receptor M1, and muscarinic acetylcholine receptor M4. Ipratropium bromide’s patent is valid until 2030-01-17 (FDA).

 

Trade Name

 

Atrovent, Atrovent Hfa
 

Common Name

 

ipratropium
 

ChEMBL ID

 

CHEMBL1621597
 

Indication

 

allergic rhinitis perennial, bronchial spasm, bronchitis, pulmonary emphysema, vasomotor rhinitis
 

Drug Class

 

Quaternary ammonium derivatives; atropine derivatives

Image (chem structure or protein)

Ipratropium structure rendering